Thursday 16 October, 2025
Introduction: The success of applications of Physiologically based pharmacokinetic (PBPK) modeling in drug development has led regulatory agencies to demand…
Read moreAbstracts
PMx-AI Bot: Changing the way of traditional Pharmacometrics work with AI Bots
Thursday 16 October, 2025
Objectives: The burgeoning influence of artificial intelligence (AI) is revolutionizing the field of pharmacometrics. This transformation is not only due…
Read morePopulation pharmacokinetics of intravenous MIT-001 in healthy subjects and patients
Thursday 16 October, 2025
Objectives: MIT-001 is a potent mitochondrial-targeting antioxidant targeting various inflammatory diseases. Utilizing pharmacokinetic (PK) and safety data from previous clinical…
Read moreAging-related CYP3A functional changes: Novel findings from a model-based assessment of real-world pharmacokinetic study in Chinese older inpatients
Thursday 16 October, 2025
Introduction: The conventional wisdom holds that oxidative CYP-mediated clearance would decrease with age, but some recent clinical trials refuted such…
Read moreA comparative analysis of Bayesian dose-finding designs incorporating pharmacokinetics information
Thursday 16 October, 2025
Introduction: In most Phase I and Phase I/II studies in patients, dose-finding and pharmacokinetics/pharmacodynamics (PK/PD) are still analyzed separately [1]….
Read moreModelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers
Thursday 16 October, 2025
Introduction Microdosing approaches allow the administration of infra-therapeutic doses of drug candidates to humans. This approach, carried out upstream of…
Read moreA comparative benchmark study of empirical tumor size models in NSCLC clinical data
Thursday 16 October, 2025
Introduction: Tumor size dynamics models are the key data analytics tools for analysis of the surrogate biomarker data in oncology…
Read moreCharacterizing the Longitudinal Exposure-Response Relationship of Upadacitinib Efficacy in Vitiligo: Insights from Analysis of Phase 2 Clinical Data
Thursday 16 October, 2025
Introduction: Upadacitinib (UPA) is an orally administered Janus Kinase inhibitor which has been approved or is in development for the…
Read moreIn vitro-in silico platform for mechanistic investigation of bile acid disposition in cultured hepatocytes
Thursday 16 October, 2025
Objectives: Drug-induced liver injury (DILI) is a relatively rare hepatic condition, yet the most frequent cause of acute liver failure in…
Read morePhysiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates
Thursday 16 October, 2025
Objectives: Human immunodeficiency virus (HIV) remains a significant global health challenge that disproportionately affects young women in sub-Saharan Africa [1]….
Read more